fibrosis – pharmaceutical daily

April 25, 2019 Off

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating…

January 28, 2017 Off

Swedish Vicore Pharma’s IPF candidate C21 becomes orphan drug in US

By Dino Mustafić

Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.

December 20, 2016 Off

Novartis, Conatus in borad deal to make treatments for liver diseases

By Dino Mustafić

Novartis and Conatus Pharmaceuticals have signed a multipurpose deal which will help the two drug makers to make liver-disease treatment,…